Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PBLS
STRONG SELLParabilis Medicines, Inc. · Healthcare · United States · $3.8B · Avg Vol: $23M/d
5
StockRankGet insider-trade alerts
Q
25
V
25
M
24
P/E (TTM)
—
ROE
—
D/E
0.2x
Dividend %
—
Loading 1Y...
PRICE (1Y)+16.7%
Close
$31.82
RSI (14)
54.6
SCORE BREAKDOWN
Quality
25
ROIC
-600.8%0.5
ROE
—N/A
GP/Assets
—N/A
Op. Margin
0.0%41.3
FCF/Assets
-153.5%0.8
Piotroski
239.0
Int. Cover
-50.0x6.3
D/E Ratio
0.22x48.3
Current Ratio
6.12x76.4
Value
25
P/E (TTM)
—N/A
EV/EBITDA
-4.2x25.0
P/FCF
—N/A
P/B
-0.2x25.0
P/S
—N/A
Div Yield
—N/A
Momentum
24
52W High %
—N/A
RS 6M
—N/A
SMA 50/200
—N/A
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
-7%18.5
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$3.8B
P/E (Forward)
-16.5x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PBLS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PBLS | Parabilis Medicines, Inc.(you) | $3.8B | 5 | STRONG SELL |
| MANE | Veradermics, Incorporated | $4.6B | 8 | STRONG SELL |
| CELC | Celcuity Inc. | $4.0B | 14 | STRONG SELL |
| GPCR | Structure Therapeutics Inc. | $3.5B | 15 | STRONG SELL |
| VERA | Vera Therapeutics, Inc. | $2.5B | 9 | STRONG SELL |
| VRDN | Viridian Therapeutics, Inc. | $2.1B | 3 | STRONG SELL |
| KLRA | Kailera Therapeutics, Inc. | $2.3B | 9 | STRONG SELL |
| KARD | Kardigan, Inc. | $1.9B | 8 | STRONG SELL |
| VKTX | Viking Therapeutics, Inc. | $4.0B | 21 | SELL |
| SRRK | Scholar Rock Holding Corporation | $5.7B | 15 | STRONG SELL |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%